Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + R-CHP in High-Grade B-Cell Lymphomas
NCT04479267Phase 2Active, not recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), high-grade B-cell lymphoma with double-hit genetics (DHL), triple-hit lymphoma (THL), double-expressor lymphoma (DEL), sponsored by Barbara Ann Karmanos Cancer Institute. Started Aug 2020; status: active, not recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)high-grade B-cell lymphoma with double-hit genetics (DHL)triple-hit lymphoma (THL)double-expressor lymphoma (DEL)
Beyond the preview
Go deeper on NCT04479267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479267.